Michael Pehl
Chief Executive Officer bei ADCendo ApS
Profil
Michael Pehl is currently the Chief Executive Officer at ADCendo ApS since 2021.
Prior to this, he was the President, Chief Executive Officer & Director at Immunomedics, Inc. from 2017 to 2019.
He was also the President-Global Hematology/Oncology at Celgene Corp.
from 2006 to 2017.
Additionally, he served as the Chief Executive Officer at GEMoaB Monoclonals GmbH.
Mr. Pehl completed his undergraduate degree from Ludwig-Maximilians-Universität München.
Aktive Positionen von Michael Pehl
Unternehmen | Position | Beginn |
---|---|---|
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Chief Executive Officer | 07.07.2021 |
Ehemalige bekannte Positionen von Michael Pehl
Unternehmen | Position | Ende |
---|---|---|
IMMUNOMEDICS, INC. | Chief Executive Officer | 23.02.2019 |
CELGENE | Corporate Officer/Principal | 21.08.2017 |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The private company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Chief Executive Officer | - |
Ausbildung von Michael Pehl
Ludwig-Maximilians-Universität München | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Immunomedics, Inc.
Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Health Technology |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The private company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Health Technology |